Structure Therapeutics (GPCR) Prepaid Assets (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Prepaid Assets of $32.1 million for Q1 2026, up 151.92% year-over-year from $12.7 million in Q1 2025, and up 33.14% quarter-over-quarter from $24.1 million in Q4 2025.
Analysis
Structure Therapeutics (GPCR) Prepaid Assets (2022 - 2026) Analysis & Trends
Structure Therapeutics' Prepaid Assets history runs 5 years deep, the most recent figure standing at $32.1 million for Q1 2026.
- In Q1 2026, Prepaid Assets rose 151.92% year-over-year to $32.1 million; the TTM figure through Mar 2026 stood at $32.1 million (up 151.92% YoY), while the FY2025 annual figure was $24.1 million, up 213.35% from the prior year.
- Prepaid Assets for Q1 2026 stood at $32.1 million, up from $24.1 million in the prior quarter.
- The five-year high for Prepaid Assets was $32.1 million in Q1 2026, with the low at $2.2 million in Q4 2022.
- The 5-year median for Prepaid Assets is $9.4 million (2024), against an average of $11.3 million.
- Peak annual rise in Prepaid Assets reached 213.35% in 2025, while the deepest fall reached 1.32% in 2025.
- Structure Therapeutics' Prepaid Assets stood at $2.2 million in 2022, then surged by 179.58% to $6.3 million in 2023, then grew by 22.4% to $7.7 million in 2024, then surged by 213.35% to $24.1 million in 2025, then soared by 33.14% to $32.1 million in 2026.
- Business Quant data shows GPCR's Prepaid Assets at $32.1 million in Q1 2026, $24.1 million in Q4 2025, and $15.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Structure Therapeutics | 10.32 Bn | 10.32 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 29.37 Mn |
| Mar 31, 2026 | 32.09 Mn |
| Dec 31, 2025 | 24.11 Mn |
| Sep 30, 2025 | 14.98 Mn |
| Jun 30, 2025 | 12.80 Mn |
| Mar 31, 2025 | 12.74 Mn |
| Dec 31, 2024 | 7.69 Mn |
| Sep 30, 2024 | 8.37 Mn |
| Jun 30, 2024 | 10.50 Mn |
| Mar 31, 2024 | 12.91 Mn |
| Dec 31, 2023 | 6.29 Mn |
| Sep 30, 2023 | 4.54 Mn |
| Jun 30, 2023 | 3.64 Mn |
| Mar 31, 2023 | 5.29 Mn |
| Dec 31, 2022 | 2.25 Mn |